Skip to main content
Premium Trial:

Request an Annual Quote

Aetna Won't Cover Noninvasive Prenatal Testing for Average-Risk Pregnancies

NEW YORK (GenomeWeb) – Aetna updated its medical policy for noninvasive prenatal testing this week, choosing not to cover screening for average-risk pregnancies. It will continue to cover NIPT for high-risk pregnancies.

In a research note published by investment bank Piper Jaffray, Senior Research Analyst William Quirk wrote that the "decision by Aetna is disappointing." The payor covers around 17.9 million lives.

The decision will impact all NIPT providers, but may particularly impact Natera, which has targeted its NIPT, Panorama, especially to the average-risk pregnancy market and has seen sales of its test in that market grow.

In its revised policy, Aetna wrote that it considers cell-free DNA testing "medically necessary for testing for fetal aneuploidy (trisomy 13, 18, and 21) in pregnant women with single gestations" who are at an elevated risk. Aetna defines that as have ultrasound findings, a history of fetal aneuploidy, a positive first trimester screening test, or women who are aged 35 years or older.

Aetna considers NIPT for average risk pregnancies, microdeletions, and rare autosomal fetal aneuploidies to be investigational and experimental because its "effectiveness has not been established" for those indications.

Quirk wrote that other insurers will also be revising their medical policies, including UnitedHealth in January. That insurer currently does not cover NIPT for average-risk pregnancies.

He added that there has been "less commercial payor progress in covering average-risk NIPT this year," though there has been progress in obtaining Medicaid reimbursement for NIPT.

"We believe Aetna (along with other payers holding out covering average risk) are waiting for [the American College of Obstetrics and Gynecologists] to formally endorse NIPT in women under 35," Quirk wrote. Currently, ACOG guidelines state that doctors may use NIPT in those women.

Shares of Natera were down around 3 percent at $10.62 in Friday afternoon trade on the Nasdaq.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.